Tweet
29th May 2023
By Frank Hossack
... The first of those is SYS6006, a mRNA vaccine developed by Shijiazhuang Pharmaceutical Group (pictured). Given market approval back in March, the vaccine was first administered in the company’s home city on 13 May.
Then there is the 4-valent vaccine developed by Beijing’s Sinocelltech, which contains the antigenic components of four variants of COVID; Alpha, Beta, Delta and Omicron.
According to a “Vaccination Work Plan for Responding to the Recent COVID Infection Epidemic”, it is recommended that two major categories and four subcategories of target groups should complete the vaccination as soon as possible to fully build up an immune barrier. ...
By Frank Hossack
... The first of those is SYS6006, a mRNA vaccine developed by Shijiazhuang Pharmaceutical Group (pictured). Given market approval back in March, the vaccine was first administered in the company’s home city on 13 May.
Then there is the 4-valent vaccine developed by Beijing’s Sinocelltech, which contains the antigenic components of four variants of COVID; Alpha, Beta, Delta and Omicron.
According to a “Vaccination Work Plan for Responding to the Recent COVID Infection Epidemic”, it is recommended that two major categories and four subcategories of target groups should complete the vaccination as soon as possible to fully build up an immune barrier. ...